EUVIMEDEUVIMED entdecken
Open Access

Prognosis Using Modified Albumin–Bilirubin Grade in Resected Biliary Tract Cancer: A Multicenter Propensity Score–matched Analysis

Toru Takahashi, Hiroaki Yanagimoto, Masayuki Akita, Daisuke Tsugawa, Michihiko Yoshida, Yasuhiro Ueda, Taro Okazaki, Kimihiko Ueno, Hayato Miyazaki, Izuru Otsubo, Shohei Komatsu, Takumi Fukumoto

Cancer Diagnosis & Prognosis · 01.07.2026 · 6 (4) · 703-714

DOI: 10.21873/cdp.10570 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Diagnosis & Prognosis, online erschienen am 01.07.2026. Verfasst von Toru Takahashi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aim: Currently, the modified albumin-bilirubin (mALBI) grade, a novel liver function assessment, is used as a prognostic factor in many areas of gastrointestinal cancer. We evaluated whether mALBI grade predicted survival in a large multicenter cohort of patients who underwent curative-intent resection for biliary tract cancer (BTC). Patients and Methods: We retrospectively analyzed data for 634 patients who underwent curative resection for BTC at four centers during 2001-2023. The mALBI grade was calculated from preoperative albumin and total bilirubin levels. Cox proportional hazards regression was used to assess the association of mALBI grade with overall survival (OS) and recurrence-free survival (RFS) in a propensity score-matched cohort. The mALBI grade was defined by subdividing ALBI grade 2 at a cutoff of −2.27; patients with mALBI grades 1-2a were classified as the low mALBI group, and those with grades 2b-3 as the high mALBI group.

Results

After propensity score-matching, the high mALBI group remained associated with poorer OS (44 vs. 70 months; p=0.015) than the low mALBI group. Multivariate analysis revealed that high mALBI grade was independently associated with poor OS (hazard ratio=1.584, 95% confidence interval=1.077-2.331; p=0.020) and RFS (hazard ratio =1.447, 95% confidence interval=1.023-2.046, p=0.037).

Conclusion

A high mALBI grade was associated with shorter OS and RFS in patients with resected BTC. Preoperative mALBI grade is an important prognostic indicator for risk stratification and prognostic evaluation.

Schlagwörter

Stichwörter der Autor:innen

Modified albumin-bilirubin gradeadjunctive therapybiliary tract cancermulticenter studyoverall survival

Autor:innen und Institutionen

  • Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Division of Gastroenterological Surgery, Hyogo Cancer Center, Hyogo, Japan.
  • Department of Surgery, National Hospital Organization Kobe Medical Center, Hyogo, Japan.
  • Department of Surgery, Akashi Medical Center, Hyogo, Japan.

Zitieren

APA

Takahashi, T., Yanagimoto, H., Akita, M., Tsugawa, D., Yoshida, M., Ueda, Y., Okazaki, T., Ueno, K., Miyazaki, H., Otsubo, I., Komatsu, S., & Fukumoto, T. (2026). Prognosis Using Modified Albumin–Bilirubin Grade in Resected Biliary Tract Cancer: A Multicenter Propensity Score–matched Analysis. Cancer Diagnosis & Prognosis, 6(4), 703-714. https://doi.org/10.21873/cdp.10570

Vancouver

Takahashi T, Yanagimoto H, Akita M, Tsugawa D, Yoshida M, Ueda Y, et al. Prognosis Using Modified Albumin–Bilirubin Grade in Resected Biliary Tract Cancer: A Multicenter Propensity Score–matched Analysis. Cancer Diagnosis & Prognosis. 2026;6(4):703-714. doi:10.21873/cdp.10570

BibTeX
@article{Takahashi2026,
  author = {Takahashi, Toru and Yanagimoto, Hiroaki and Akita, Masayuki and Tsugawa, Daisuke and Yoshida, Michihiko and Ueda, Yasuhiro and Okazaki, Taro and Ueno, Kimihiko and Miyazaki, Hayato and Otsubo, Izuru and Komatsu, Shohei and Fukumoto, Takumi},
  title = {Prognosis Using Modified Albumin–Bilirubin Grade in Resected Biliary Tract Cancer: A Multicenter Propensity Score–matched Analysis},
  journal = {Cancer Diagnosis & Prognosis},
  year = {2026},
  volume = {6},
  number = {4},
  pages = {703--714},
  doi = {10.21873/cdp.10570}
}
Kostenlos starten →